哥伦比亚类风湿关节炎患者临床改善的多变量预测模型的建立和评价。

IF 3.4 2区 医学 Q2 RHEUMATOLOGY
Therapeutic Advances in Musculoskeletal Disease Pub Date : 2025-06-16 eCollection Date: 2025-01-01 DOI:10.1177/1759720X251342426
Claudia Ibáñez-Antequera, Gabriel-Santiago Rodríguez-Vargas, Fernando Rodríguez-Florido, Pedro Rodríguez-Linares, Adriana Rojas-Villarraga, Pedro Santos-Moreno
{"title":"哥伦比亚类风湿关节炎患者临床改善的多变量预测模型的建立和评价。","authors":"Claudia Ibáñez-Antequera, Gabriel-Santiago Rodríguez-Vargas, Fernando Rodríguez-Florido, Pedro Rodríguez-Linares, Adriana Rojas-Villarraga, Pedro Santos-Moreno","doi":"10.1177/1759720X251342426","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease, and a predicting clinical improvement is essential.</p><p><strong>Objectives: </strong>The aim of the present study was to identify predictor variables of clinical improvement in patients with RA using artificial intelligence (AI) models in a specialized RA center.</p><p><strong>Design: </strong>Retrospective cohort study in adult RA patients was conducted between January and June 2022. Follow-up data related to clinical improvement was taken from 6 to 12 months after the baseline. Predictive models were generated by machine learning (ML), by Python programming language. The Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines were followed to harmonize this study based on AI.</p><p><strong>Methods: </strong>The response variable was classified as improved and non-improved. Patients were considered improved if they persisted or achieved a Disease Activity Score 28-joints (DAS28) <3.2 at the end of the follow-up period or experienced a decrease ⩾0.6 compared to baseline, regardless of the initial DAS28 value. Explainability techniques in AI were applied to identify the most relevant clinical features.</p><p><strong>Results: </strong>In total, 3161 RA patients were included. The median age was 65 years (interquartile range (IQR) 57-72). 82.7% were female. Disease duration was 8.3 years (IQR 4.9-11.3). The median value of baseline DAS28 was 2.1 (IQR 2.1-2.8). 2668 (84.4%) were classified as improved, and 493 (15.6%) as non-improved. From ML models, the Extra tree model showed higher sensitivity (0.841). Regarding clinical improvement prediction with the Shapley Additive Explanations method, it was observed that low values of baseline DAS28 were positively associated with clinical improvement. The use of biologic disease-modifying antirheumatic drugs and the presence of anti-cyclic citrullinated peptide (CCP) were related to an increase in the probability of non-improved, which may be secondary to the level of severity of the disease.</p><p><strong>Conclusion: </strong>AI models in RA can predict clinical improvement at initial consultations, enabling targeted approaches. Disease severity may be influenced by anti-CCP positivity and the use of biologic therapies when conventional treatments fail.</p>","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"17 ","pages":"1759720X251342426"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174781/pdf/","citationCount":"0","resultStr":"{\"title\":\"Development and evaluation of a multivariable prediction model for clinical improvement in an established cohort of Colombian rheumatoid arthritis patients.\",\"authors\":\"Claudia Ibáñez-Antequera, Gabriel-Santiago Rodríguez-Vargas, Fernando Rodríguez-Florido, Pedro Rodríguez-Linares, Adriana Rojas-Villarraga, Pedro Santos-Moreno\",\"doi\":\"10.1177/1759720X251342426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease, and a predicting clinical improvement is essential.</p><p><strong>Objectives: </strong>The aim of the present study was to identify predictor variables of clinical improvement in patients with RA using artificial intelligence (AI) models in a specialized RA center.</p><p><strong>Design: </strong>Retrospective cohort study in adult RA patients was conducted between January and June 2022. Follow-up data related to clinical improvement was taken from 6 to 12 months after the baseline. Predictive models were generated by machine learning (ML), by Python programming language. The Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines were followed to harmonize this study based on AI.</p><p><strong>Methods: </strong>The response variable was classified as improved and non-improved. Patients were considered improved if they persisted or achieved a Disease Activity Score 28-joints (DAS28) <3.2 at the end of the follow-up period or experienced a decrease ⩾0.6 compared to baseline, regardless of the initial DAS28 value. Explainability techniques in AI were applied to identify the most relevant clinical features.</p><p><strong>Results: </strong>In total, 3161 RA patients were included. The median age was 65 years (interquartile range (IQR) 57-72). 82.7% were female. Disease duration was 8.3 years (IQR 4.9-11.3). The median value of baseline DAS28 was 2.1 (IQR 2.1-2.8). 2668 (84.4%) were classified as improved, and 493 (15.6%) as non-improved. From ML models, the Extra tree model showed higher sensitivity (0.841). Regarding clinical improvement prediction with the Shapley Additive Explanations method, it was observed that low values of baseline DAS28 were positively associated with clinical improvement. The use of biologic disease-modifying antirheumatic drugs and the presence of anti-cyclic citrullinated peptide (CCP) were related to an increase in the probability of non-improved, which may be secondary to the level of severity of the disease.</p><p><strong>Conclusion: </strong>AI models in RA can predict clinical improvement at initial consultations, enabling targeted approaches. Disease severity may be influenced by anti-CCP positivity and the use of biologic therapies when conventional treatments fail.</p>\",\"PeriodicalId\":23056,\"journal\":{\"name\":\"Therapeutic Advances in Musculoskeletal Disease\",\"volume\":\"17 \",\"pages\":\"1759720X251342426\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174781/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Musculoskeletal Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1759720X251342426\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X251342426","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:类风湿关节炎(RA)是一种慢性自身免疫性疾病,对其临床改善进行预测至关重要。目的:本研究的目的是在专门的RA中心使用人工智能(AI)模型确定RA患者临床改善的预测变量。设计:在2022年1月至6月期间对成人RA患者进行回顾性队列研究。基线后6至12个月随访临床改善相关数据。预测模型通过机器学习(ML),通过Python编程语言生成。遵循透明报告个体预后或诊断的多变量预测模型(TRIPOD)指南,以协调基于人工智能的研究。方法:将反应变量分为改善型和非改善型。如果患者坚持或达到疾病活动评分28关节(DAS28),则认为患者得到改善。结果:总共纳入3161例RA患者。中位年龄为65岁(四分位间距(IQR) 57-72)。82.7%为女性。病程8.3年(IQR 4.9 ~ 11.3)。基线DAS28中位值为2.1 (IQR为2.1-2.8)。改善2668例(84.4%),未改善493例(15.6%)。从ML模型来看,Extra树模型具有更高的灵敏度(0.841)。对于Shapley加性解释法的临床改善预测,我们观察到基线DAS28的低值与临床改善呈正相关。生物疾病改善抗风湿药物的使用和抗环瓜氨酸肽(CCP)的存在与未改善的概率增加有关,这可能是继发于疾病严重程度的。结论:RA的AI模型可以在初步会诊时预测临床改善,从而实现有针对性的治疗。当常规治疗失败时,抗ccp阳性和生物治疗的使用可能会影响疾病的严重程度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development and evaluation of a multivariable prediction model for clinical improvement in an established cohort of Colombian rheumatoid arthritis patients.

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease, and a predicting clinical improvement is essential.

Objectives: The aim of the present study was to identify predictor variables of clinical improvement in patients with RA using artificial intelligence (AI) models in a specialized RA center.

Design: Retrospective cohort study in adult RA patients was conducted between January and June 2022. Follow-up data related to clinical improvement was taken from 6 to 12 months after the baseline. Predictive models were generated by machine learning (ML), by Python programming language. The Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines were followed to harmonize this study based on AI.

Methods: The response variable was classified as improved and non-improved. Patients were considered improved if they persisted or achieved a Disease Activity Score 28-joints (DAS28) <3.2 at the end of the follow-up period or experienced a decrease ⩾0.6 compared to baseline, regardless of the initial DAS28 value. Explainability techniques in AI were applied to identify the most relevant clinical features.

Results: In total, 3161 RA patients were included. The median age was 65 years (interquartile range (IQR) 57-72). 82.7% were female. Disease duration was 8.3 years (IQR 4.9-11.3). The median value of baseline DAS28 was 2.1 (IQR 2.1-2.8). 2668 (84.4%) were classified as improved, and 493 (15.6%) as non-improved. From ML models, the Extra tree model showed higher sensitivity (0.841). Regarding clinical improvement prediction with the Shapley Additive Explanations method, it was observed that low values of baseline DAS28 were positively associated with clinical improvement. The use of biologic disease-modifying antirheumatic drugs and the presence of anti-cyclic citrullinated peptide (CCP) were related to an increase in the probability of non-improved, which may be secondary to the level of severity of the disease.

Conclusion: AI models in RA can predict clinical improvement at initial consultations, enabling targeted approaches. Disease severity may be influenced by anti-CCP positivity and the use of biologic therapies when conventional treatments fail.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.80
自引率
4.80%
发文量
132
审稿时长
18 weeks
期刊介绍: Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信